Legend Biotech USA presented updated first-in-human CAR T data for LB-2501 at EHA2026, positioning the CD19/CD20 dual-targeting therapy as a potential first-in-class, off-the-shelf option that could be used without lymphodepletion in an outpatient setting. In the trial update, 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma received treatment at two dose levels. At the higher dose, all six treated patients responded, including five complete responses and one partial response. The company also reported that some patients converted from partial response to complete response over time. Safety signals remained comparatively limited in the update, with adverse events increasing between dose levels but the highest grade reported so far at grade two and no neurotoxicity observed. Legend CEO Ying Huang characterized the low toxicity to date as “pleasant surprise,” contrasting it with higher rates of grade 3+ adverse events typically seen with autologous CAR T. For the CAR T pipeline, the trial supports a shift toward simplifying administration logistics—single infusion and potential outpatient use—while maintaining deep response rates in an early clinical setting.